Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Press release — No. 18 / 2026Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & EndocrinologyCopenhagen, Denmark, September 30, 2026 — Zealand Pharma A/S NASDAQ:ZEAL (CVR-no. 200450…